417 related articles for article (PubMed ID: 34761360)
41. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.
Clarke A; Pulikottil-Jacob R; Grove A; Freeman K; Mistry H; Tsertsvadze A; Connock M; Court R; Kandala NB; Costa M; Suri G; Metcalfe D; Crowther M; Morrow S; Johnson S; Sutcliffe P
Health Technol Assess; 2015 Jan; 19(10):1-668, vii-viii. PubMed ID: 25634033
[TBL] [Abstract][Full Text] [Related]
42. Sex Difference in Spinal Muscular Atrophy Patients - are Males More Vulnerable?
Sun J; Harrington MA; Porter B;
J Neuromuscul Dis; 2023; 10(5):847-867. PubMed ID: 37393514
[TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands.
Velikanova R; van der Schans S; Bischof M; van Olden RW; Postma M; Boersma C
Value Health; 2022 Oct; 25(10):1696-1704. PubMed ID: 35963838
[TBL] [Abstract][Full Text] [Related]
44. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.
Wadman RI; Wijngaarde CA; Stam M; Bartels B; Otto LAM; Lemmink HH; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
Eur J Neurol; 2018 Mar; 25(3):512-518. PubMed ID: 29194869
[TBL] [Abstract][Full Text] [Related]
45. Quality of life of patients with spinal muscular atrophy: A systematic review.
Landfeldt E; Edström J; Sejersen T; Tulinius M; Lochmüller H; Kirschner J
Eur J Paediatr Neurol; 2019 May; 23(3):347-356. PubMed ID: 30962132
[TBL] [Abstract][Full Text] [Related]
46. Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease).
Salort-Campana E; Quijano-Roy S
Arch Pediatr; 2020 Dec; 27(7S):7S23-7S28. PubMed ID: 33357593
[TBL] [Abstract][Full Text] [Related]
47. Long-term exercise-specific neuroprotection in spinal muscular atrophy-like mice.
Chali F; Desseille C; Houdebine L; Benoit E; Rouquet T; Bariohay B; Lopes P; Branchu J; Della Gaspera B; Pariset C; Chanoine C; Charbonnier F; Biondi O
J Physiol; 2016 Apr; 594(7):1931-52. PubMed ID: 26915343
[TBL] [Abstract][Full Text] [Related]
48. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
49. Spinal Muscular Atrophy Type III Recognized After Delayed Recovery From Neuromuscular Blockade After an Orthognathic Surgery.
Oda A; Oue K; Yoshida M
J Craniofac Surg; 2023 Sep; 34(6):e580-e582. PubMed ID: 37253240
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation.
Pandor A; Goodacre S; Harnan S; Holmes M; Pickering A; Fitzgerald P; Rees A; Stevenson M
Health Technol Assess; 2011 Aug; 15(27):1-202. PubMed ID: 21806873
[TBL] [Abstract][Full Text] [Related]
51. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006281. PubMed ID: 22513939
[TBL] [Abstract][Full Text] [Related]
52. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006281. PubMed ID: 22161399
[TBL] [Abstract][Full Text] [Related]
53. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
54. Functional and surgical treatments in patients with spinal muscular atrophy (SMA).
Boulay C; Peltier E; Jouve JL; Pesenti S
Arch Pediatr; 2020 Dec; 27(7S):7S35-7S39. PubMed ID: 33357596
[TBL] [Abstract][Full Text] [Related]
55. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006282. PubMed ID: 22513940
[TBL] [Abstract][Full Text] [Related]
56. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006282. PubMed ID: 22161400
[TBL] [Abstract][Full Text] [Related]
57. Ultrastructural characterization of peripheral denervation in a mouse model of Type III spinal muscular atrophy.
Fulceri F; Biagioni F; Limanaqi F; Busceti CL; Ryskalin L; Lenzi P; Fornai F
J Neural Transm (Vienna); 2021 Jun; 128(6):771-791. PubMed ID: 33999256
[TBL] [Abstract][Full Text] [Related]
58. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
[TBL] [Abstract][Full Text] [Related]
59. The economic burden of head and neck cancer: a systematic literature review.
Wissinger E; Griebsch I; Lungershausen J; Foster T; Pashos CL
Pharmacoeconomics; 2014 Sep; 32(9):865-82. PubMed ID: 24842794
[TBL] [Abstract][Full Text] [Related]
60. Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review.
Gavriilaki M; Papaliagkas V; Stamperna A; Moschou M; Notas K; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
Acta Neurol Belg; 2023 Oct; 123(5):1735-1745. PubMed ID: 35861914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
